Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Claudia Chiriches"'
Autor:
Ecmel Mehmetbeyoglu, Claudia Chiriches, Imran Shair Mohammed, Beyza Nur Onat, Kadir Yaray, Oguz Galip Yildiz, Serpil Taheri, Martin Ruthardt
Publikováno v:
HemaSphere, Vol 7, p e69134db (2023)
Externí odkaz:
https://doaj.org/article/61ee5b602f77466f98220b3674253c2e
Publikováno v:
HemaSphere, Vol 7, p e93079e9 (2023)
Externí odkaz:
https://doaj.org/article/4171f44dcfd34a51a5c9c8b1c447eeff
Autor:
Claudia Chiriches, Nathalie Nicolaisen, Maria Wieske, Heba Elhaddad, Ecmel Mehmetbeyoglu, Caroline Alvares, Dörte Becher, Paul Hole, Oliver Gerhard Ottmann, Martin Ruthardt
Publikováno v:
PLoS Genetics, Vol 18, Iss 10, p e1010463 (2022)
The WHO classifies t(6;9)-positive acute myeloid leukemia (AML) as a subgroup of high-risk AML because of its clinical and biological peculiarities, such as young age and therapy resistance. t(6;9) encodes the DEK/NUP214 fusion oncoprotein that targe
Externí odkaz:
https://doaj.org/article/b9784da331f645fe9b92d4e7d5409c3f
Autor:
Claudia Chiriches, Dilawar Khan, Maria Wieske, Nathalie Guillen, Michal Rokicki, Carol Guy, Marieangela Wilson, Kate J. Heesom, Oliver Gerhard Ottmann, Martin Ruthardt
Patients within the WHO-subgroup of t(6;9)-positive acute myeloid leukemia (AML) differ from other AML subgroups as they are characterised by younger age and a grim prognosis. Leukemic transformation can often be attributed to single chromosomal aber
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62c32fa14515f5be58a1c40634745b85
https://orca.cardiff.ac.uk/id/eprint/151862/1/Chiriches2022_Article_ActivationOfSignalingPathwaysI.pdf
https://orca.cardiff.ac.uk/id/eprint/151862/1/Chiriches2022_Article_ActivationOfSignalingPathwaysI.pdf
Autor:
Ricardo M. Biondi, Claudia Chiriches, Elizabeh Eshel, Oliver G. Ottmann, Larissa Pietsch, Dally Najib, Isabella Haberbosch, Martin Ruthardt, Oliver Hantschel, Abed Agbarya, Jamal Mahajna, Afsar Ali Mian, Hazem Khamaisie
Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome–positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common “gatekeeper” mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::065257f72ea9b48d1b46e14465a4f7c1
https://orca.cardiff.ac.uk/id/eprint/136955/8/Mian2021_Article_CrizotinibActsAsABL1InhibitorC.pdf
https://orca.cardiff.ac.uk/id/eprint/136955/8/Mian2021_Article_CrizotinibActsAsABL1InhibitorC.pdf
Autor:
Afsar Ali, Mian, Isabella, Haberbosch, Hazem, Khamaisie, Abed, Agbarya, Larissa, Pietsch, Elizabeh, Eshel, Dally, Najib, Claudia, Chiriches, Oliver Gerhard, Ottmann, Oliver, Hantschel, Ricardo M, Biondi, Martin, Ruthardt, Jamal, Mahajna
Publikováno v:
Annals of Hematology
Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome–positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common “gatekeeper” mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9c713ae1181071ce445731d4bcbdc0f4
https://pubmed.ncbi.nlm.nih.gov/34110462
https://pubmed.ncbi.nlm.nih.gov/34110462
Autor:
Marieangela C. Wilson, Nathalie Guillen, Hannelore Held, Afsar Ali Mian, Paul S. Hole, Oliver G. Ottmann, Claudia Chiriches, Martin Ruthardt, Maria Wieske, Caroline Alvares, Dörte Becher, Andreas Otto, Carol Guy, Kate J. Heesom, Michal Jaroslaw Rokicki
SummaryAcute myeloid leukemias (AML) are characterized by recurrent genomic alterations, often in transcriptional regulators, which form the basis on which current prognostication and therapeutic intervention is overlaid. In AML transformation can of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cf55821ad18a69502c3763b2fb85382
https://doi.org/10.1101/464958
https://doi.org/10.1101/464958
Autor:
Claudia Chiriches, Nathalie Guillen, Martin Ruthardt, Michal Jaroslaw Rokicki, Afsar Ali Mian, Oliver G. Ottmann, Carol Guy
Publikováno v:
Blood. 132:3917-3917
Acute myeloid leukemias (AML) are characterized by recurrent genomic alterations, often in transcriptional regulators, which form the basis on which current prognostication and therapeutic intervention is overlaid. Three subtypes of AML carrying spec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8267f5fef07cc8245adc0b48595ed566
https://doi.org/10.1182/blood-2018-99-116631
https://doi.org/10.1182/blood-2018-99-116631
Autor:
Afsar Ali Mian, Dilawar Khan, Michal Jaroslaw Rokicki, Carol Guy, Nathalie Guillen, Claudia Chiriches, Oliver G. Ottmann, Martin Ruthardt
Publikováno v:
Blood. 128:2746-2746
Resistance to therapy including potent and selective targeted agents remains the major clinical challenge in AML. In fact, allogeneic stem cell transplantation remains the best curative treatment option for AML patients with high-risk features. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63e39f90ee4cd3bd75defb49d16fc617
https://doi.org/10.1182/blood.v128.22.2746.2746
https://doi.org/10.1182/blood.v128.22.2746.2746